Zepbound Plus Amylin Drug Drives 23% Weight Loss in Diabetes Patients
Eli Lilly's GLP-1 and amylin combination therapy outperformed either drug alone, cutting body weight by 23% over 48 weeks.
Summary
Eli Lilly tested a combination of its GLP-1 drug Zepbound with eloralintide, an amylin-targeting drug, in people with obesity and type 2 diabetes. After 48 weeks, participants on the highest dose combination lost 23.3% of their body weight — significantly more than those on Zepbound alone (14.8%) or eloralintide alone (11.1%). This is notable because people with type 2 diabetes typically lose less weight on obesity medications than those without diabetes. However, high dropout rates among participants raise concerns about how well the combination is tolerated, which could affect its path to approval and real-world use.
Detailed Summary
Obesity and type 2 diabetes are two of the most significant drivers of accelerated aging and reduced healthspan, making effective weight-loss therapies a major longevity priority. Eli Lilly's latest mid-stage trial data suggests a new combination approach could meaningfully advance what is pharmacologically possible.
The trial tested multiple doses of Zepbound (tirzepatide), Lilly's approved GLP-1/GIP dual agonist, combined with eloralintide, an investigational drug that mimics the amylin hormone — a peptide co-secreted with insulin that helps regulate appetite and glucose metabolism. Results were presented at the European Association for the Study of Diabetes annual meeting.
After 48 weeks, participants on the highest dose of the combination therapy achieved 23.3% body weight reduction. This compared favorably to 14.8% for Zepbound alone and 11.1% for eloralintide alone, suggesting meaningful additive or synergistic effects between GLP-1/GIP and amylin pathways. The magnitude is especially striking given that type 2 diabetes typically blunts weight-loss responses to obesity medications.
Despite these impressive numbers, the trial's high discontinuation rate is a critical caveat. A substantial proportion of participants stopped treatment before the study concluded, raising questions about side-effect burden — likely nausea, vomiting, and gastrointestinal distress, common with this drug class. If tolerability cannot be improved, real-world utility may be limited even if efficacy data look strong.
For health-conscious adults, this research signals that the next generation of obesity pharmacotherapy may push weight loss well beyond what current single-agent GLP-1 drugs achieve, with potential downstream benefits for metabolic health, cardiovascular risk, and biological aging. However, the findings are mid-stage and preliminary; larger Phase 3 trials with full safety and tolerability data will be essential before clinical translation.
Key Findings
- Combination of Zepbound and eloralintide produced 23.3% weight loss over 48 weeks in type 2 diabetes patients.
- The combination outperformed Zepbound alone (14.8%) and eloralintide alone (11.1%) at highest doses.
- Results are especially notable as type 2 diabetes typically reduces weight-loss responses to GLP-1 drugs.
- High treatment discontinuation rates raise tolerability concerns that could limit real-world adoption.
- Targeting both GLP-1/GIP and amylin pathways simultaneously may offer additive metabolic benefits.
Methodology
This is a news report summarizing mid-stage (Phase 2) clinical trial results presented at a major diabetes conference. The source, STAT News, is a credible specialized health and science outlet. The article is based on conference-presented data; full peer-reviewed publication has not been confirmed.
Study Limitations
The article is paywalled after a brief summary, so full trial design, sample size, dropout rates, and safety data are not accessible here. Results are conference presentations, not yet peer-reviewed. Discontinuation rates and their causes require scrutiny in the full dataset.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: